

IN THE UNI

STATES PATENT AND TRA

MARK OFFICE

Applicants: Elazar Rabbani et al. )  
Serial No. 08/978,636 )  
Filed: November 25, 1997 )  
Title NOVEL PROPERTY EFFECTING )  
AND/OR PROPERTY EXHIBITING )  
COMPOSITIONS FOR THERAPEUTIC )  
AND DIAGNOSTIC USE )



Group Art Unit: 1635

Ex'r: Andrew Wang

527 Madison Avenue, 9th Floor  
New York, New York 10022  
October 26, 1998

FILED BY EXPRESS MAIL

Honorable Commissioner  
of Patents and Trademarks  
Washington, D.C. 20231

Attention: Box Sequence

COMMUNICATION DIRECTED TO NOTICE  
TO COMPLY WITH SEQUENCE RULES


Dear Sirs:

This Communication is directed to the Notice To Comply With Sequence Rules that was attached to the Notice to File Missing Parts of Application – Filing Date Granted that was mailed on April 24, 1998 in connection with the above-identified application.

In response to the sequence notice, Applicants hereby submit the following documents or items:

1. A Request For An Extension Of Time (Five Months) Under 37 C.F.R. §1.136(a);
2. A copy of the Notice To Comply With Requirements For Patent Application Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures Under 37 C.F.R. §§1.821 - 1.825.

ENZ-53(D3)

EXPRESS MAIL CERTIFICATE	
Express Mail Label No. EM366566219	
OCTOBER 26, 1998	
I hereby certify that the above and the attachments herein were sent by the United States Postal Service as Express Mail in the Office to the Commissioner of Patents and Trademarks, Washington, DC 20231 on the date above indicated, addressed to the Commissioner of Patents and Trademarks, Washington DC 20231	
	OCT 26 98
Ronald C. Fedus Reg. No. 32,567	

Elazar Rabbani et al.  
Serial No. 08/978,635  
Filed: November 25, 1997  
Page 2 (Communication Directed to Notice to Comply With Sequence Rules -  
October 26, 1998)

3. initial paper copy of the "Sequence Listing;"
4. Amendment directing entry of the "Sequence Listing" into the specification;
5. computer readable form (CFR) copy of the "Sequence Listing;" and
6. Declaration Under 37 C.F.R. §1.821(g) attesting that the content of the paper and computer readable copies are the same and include no new matter.

No fee is believed due in connection with this Communication or the documents or items submitted herewith other than the fee payment authorized in the Request For an Extension Of time (Five Months) Under 37 C.F.R. §1.136(a). If any other fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

If helpful to processing this Communication, the undersigned may be contacted by telephone at (212) 583-0100 during the daytime hours.

Respectfully submitted,



Ronald C. Fedus  
Registration No. 32,567  
Attorney for Applicants

ENZO THERAPEUTICS, INC  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9<sup>th</sup> Fl.)  
New York, New York 10022  
(212) 583-0100

LC/USProsecution/Enz53(D3)6/communication re sequence rules102398 3nz53d3

ENZ-53(D3)